HC Wainwright & Co. Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) but lowers the price target from $34 to $20.

August 12, 2024 | 7:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Checkpoint Therapeutics but lowers the price target from $34 to $20.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for future performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100